Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01075256
Other study ID # Z3690607
Secondary ID
Status Completed
Phase Phase 4
First received February 23, 2010
Last updated April 25, 2013
Start date December 2008
Est. completion date March 2009

Study information

Verified date April 2013
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

To evaluate the efficacy of two different concentrations of a tubule occlusion agent - calcium sodium phosphosilicate in treatment of dentine hypersensitivity


Description:

Dentine hypersensitivity is characterized by short, sharp pain arising from exposed dentine typically in response to chemical, thermal, tactile or osmotic stimuli. Dentine hypersensitivity may be treated by either making the nerve in the tooth less sensitive or by occluding the tubules to limit exposure of the nerve to external stimuli. Bioactive and biocompatible glasses react with oral fluid to deposit a mineral that is chemically analogous to that found in both enamel and dentine thus preventing exposure of the nerve to external stimuli.

A number of controlled clinical trials have been reported indicating that a calcium sodium phosphosilicate bioactive glass, when incorporated into a toothpaste formulation, significantly reduce pain from dentine hypersensitivity. The aim of this study is to evaluate the effectiveness of two currently marketed toothpastes, containing 5% calcium sodium phosphosilicate and the other containing 7.5% calcium sodium phosphosilicate in the treatment of dentine hypersensitivity compared to a matched placebo control.


Recruitment information / eligibility

Status Completed
Enrollment 195
Est. completion date March 2009
Est. primary completion date March 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

1. Consent: Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.

2. Age: Aged between 20 - 50 years.

3. General Health: Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history.

4. Contraception: Females of childbearing potential who are, in the opinion of the investigator, practising a reliable method of contraception.

5. Erosion/Abrasion/Recession:Study teeth must show signs of facial/cervical erosion, abrasion and/or gingival recession.

6. Gingival Health / Tooth Mobility Grade:Study teeth must have Löe and Silness Gingival Index (GI) score less than or equal to 2 and clinical mobility less than or equal to grade I.

7. Current Product Use: Participants must have been using the same brand of toothpaste for at least 2 months and should not have used desensitizing toothpaste during the 4 weeks preceding screening. Participants will be required to bring in their current toothpaste(s) in order to verify the ingredients.

8. VAS Training: Successfully completes the VAS training exercise at Screening.

9. Sensitivity: Self-reported history of dentinal hypersensitivity and a primary complaint of sensitive teeth lasting a maximum of 10 years. At Screening: A minimum of 5 evaporative (air) sensitive lateral incisors, canines or pre-molars must display a response greater than 25 mm on a 100 mm VAS. At Baseline: A minimum of 3 of the 5 evaporative (air) sensitive teeth identified at screening must display a response greater than 25 mm on a 100 mm VAS. All teeth meeting the sensitivity Inclusion Criteria will be followed and assessed using both efficacy parameters.

10. Compliance: Understands and is willing, able and likely to comply with all study procedures and restrictions.

Exclusion Criteria:

1. Pregnancy: Women who are known to be pregnant or who are intending to become pregnant over the duration of the study.

2. Breast-feeding: Women who are breast-feeding.

3. Medical History: a) Chronic debilitating disease is present b)Chronic disease or other condition is present that is associated with intermittent episodes or constant daily pain, such as arthritis, low back pain, dysmenorrhea, etc.

4. Medications: Daily doses of medication, which in the opinion of the investigator, might interfere with the perception of pain, are being taken. Examples of such medications include analgesics, anticonvulsants, antihistamines that cause marked or moderate sedation, sedatives, tranquilizers, mood-altering and anti-inflammatory drugs.

5. Dentition Exclusions: a) Sensitive teeth not expected to respond to treatment with an over-the- counter (OTC) dentifrice in the opinion of the investigator. b) Teeth with exposed dentine but with deep, defective or facial restorations, teeth used as abutments for fixed or removable partial dentures, teeth with full crowns, orthodontic bands, extensive caries or cracked enamel. Sensitive teeth with contributing aetiologies other than erosion, abrasion or recession of exposed dentine. c) Dental professional hygiene (includes dental prophylaxis, irrigation, and intensive anti-microbial/anti-biotic therapy) within 14 days of the screening visit. d) Presence of dental implants. e) Lip or tongue piercings. f) Periodontal surgical history within the past 6 months or have been scaled /root planed within the past 3 months.

6. Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.

7. Clinical Study/Experimental Medication: a) Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit.b) Previous participation in this study.

8. Xerostomia: Any condition or medication that causes xerostomia.

9. Personnel: An employee of the sponsor or the study site or members of their immediate family.

10. Other: Any subject who in the opinion of the investigator, should not participate in the study.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Intervention

Device:
5% calcium sodium phosphosilicate toothpaste
Low concentration calcium sodium phosphosilicate tubule occlusion agent
7.5% calcium sodium phosphosilicate toothpaste
High concentration calcium sodium phosphosilicate tubule occlusion agent
Placebo toothpaste
Placebo toothpaste

Locations

Country Name City State
United States University Park Research Center (UPRC) Fort Wayne Indiana

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Adjusted Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a VAS at Day 10 Response to a constant jet of air applied to a hypersensitive tooth was evaluated using a 100mm VAS pain response scale. According to this analog scale, pain response for stimulated tooth ranged from 0 (no pain) to 100 (intense pain). Change from baseline in pain response was calculated using VAS score and a change of greater than 25 mm in VAS indicates potential relevant clinical significance of treatment. Baseline to Day 10 No
Other Adjusted Mean Change From Baseline in Cold Water Sensitivity Pain Response on a VAS at Day 10 Response of exposed dentine surface to application of 1 ml freshly melted ice cold water was evaluated using a 100 mm VAS pain response scale. According to this analog scale, pain response for stimulated tooth ranged from 0 (no pain) to 100 (intense pain). Change from baseline in pain response was calculated using VAS score and a change of greater than 25 mm in VAS indicates potential relevant clinical significance of treatment. Baseline to Day 10 No
Other Adjusted Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a VAS at Day 3 Response to a constant jet of air applied to a hypersensitive tooth was evaluated using a 100 mm VAS pain response scale. According to this analog scale, pain response for stimulated tooth ranged from 0 (no pain) to 100 (intense pain). Change from baseline in pain response was calculated using VAS score and a change of greater than 25 mm in VAS indicates potential relevant clinical significance of treatment. Baseline to Day 3 No
Other Adjusted Mean Change From Baseline in Cold Water Sensitivity Pain Response on a VAS at Day 3 Response of exposed dentine surface to application of 1 ml freshly melted ice cold water was evaluated using a 100 mm VAS pain response scale. According to this analog scale, pain response for stimulated tooth ranged from 0 (no pain) to 100 (intense pain). Change from baseline in pain response was calculated using VAS score and a change of greater than 25 mm in VAS indicates potential relevant clinical significance of treatment. Baseline to Day 3 No
Primary Adjusted Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a Visual Analog Scale (VAS) at Day 15 Response to a constant jet of air applied to a hypersensitive tooth was evaluated using a 100 millimeter (mm) VAS pain response scale. According to this analog scale, pain response for stimulated tooth ranged from 0 (no pain) to 100 (intense pain). Change from baseline in pain response was calculated using VAS score and a change of greater than 25 mm in VAS indicates potential relevant clinical significance of treatment. Baseline to Day 15 No
Primary Adjusted Mean Change From Baseline in Cold Water Sensitivity Pain Response on a VAS at Day 15 Response of exposed dentine surface to application of 1 ml freshly melted ice cold water was evaluated using a 100 mm VAS pain response scale. According to this analog scale, pain response for stimulated tooth ranged from 0 (no pain) to 100 (intense pain). Change from baseline in pain response was calculated using VAS score and a change of greater than 25 mm in VAS indicates potential relevant clinical significance of treatment. Baseline to Day 15 No
Secondary Adjusted Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a VAS at Day 7 Response to a constant jet of air applied to a hypersensitive tooth was evaluated using a 100 millimeter (mm) VAS pain response scale. According to this analog scale, pain response for stimulated tooth ranged from 0 (no pain) to 100 (intense pain). Change from baseline in pain response was calculated using VAS score and a change of greater than 25 mm in VAS indicates potential relevant clinical significance of treatment. Baseline to Day 7 No
Secondary Adjusted Mean Change From Baseline in Cold Water Sensitivity Pain Response on a VAS at Day 7 Response of exposed dentine surface to application of 1 ml freshly melted ice cold water was evaluated using a 100 mm VAS pain response scale. According to this analog scale, pain response for stimulated tooth ranged from 0 (no pain) to 100 (intense pain). Change from baseline in pain response was calculated using VAS score and a change of greater than 25 mm in VAS indicates potential relevant clinical significance of treatment. Baseline to Day 7 No
See also
  Status Clinical Trial Phase
Completed NCT00985439 - Study of Diclofenac Capsules to Treat Dental Pain Phase 2
Completed NCT00943098 - Evaluation of the Efficacy and Safety of Diclofenac HPBCD 75mg/ml in Treatment of Pain Following Dental Surgery Phase 3
Completed NCT00954356 - Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction Phase 2
Completed NCT00942448 - Evaluation of the Efficacy and Safety of Diclofenac HPBCD 25, 50 mg/ml in the Treatment of Post-surgical Pain Following Dental Surgery Phase 3
Completed NCT02966067 - A Split Mouth Trial to Compare Microneedles vs. Standard Needles in Dental Anaesthetic Delivery N/A
Completed NCT01960114 - Study of Long-Acting Acetaminophen in Postoperative Dental Pain Phase 2
Completed NCT01229228 - Study of Naproxen Capsules to Treat Dental Pain Phase 2
Completed NCT01177423 - Efficiency Evaluation of Intradiploic Intra-osseus Anesthesia Versus Inferior Alveolar Nerve Block N/A
Completed NCT03328208 - Nonpharmacologic Reduction of Periprocedural Distress and Drug Use N/A
Completed NCT05236101 - Validation of Child Drawing Hospital Scale (CD: H) and the Place of the Drawing in the Evaluation of Dental Anxiety N/A
Completed NCT00542035 - A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction Phase 2
Completed NCT04231955 - Comparison of Different Pain Rating Scales in Patients With Symptomatic Teeth N/A
Completed NCT02096926 - Methodological Validation of Ibuprofen Verses Placebo for Post Operative Pain After Third Molar Extraction Surgery Phase 4
Completed NCT05369936 - Pain Perception: on Relationships Between Dental Anxiety and Olfaction N/A
Recruiting NCT05351099 - Dental Block for Pain Relief in ED Dental Pain Patients
Not yet recruiting NCT06269406 - A Combination of Ibuprofen With Curcumin Covered With Liquorice Root Supplementation in the Management of Postoperative Dental Pain in Adults N/A
Recruiting NCT05443009 - Self-Reported Pain in Children Submitted to Single Infiltration of Articaine During Primary Molar Extraction Phase 4
Terminated NCT02161354 - Safety and Efficacy Study of NTC-510 to Treat Pain Following Dental Surgery of Third Molars Phase 2
Completed NCT04949126 - Self Medication in Odontology (AUDE)
Completed NCT03652818 - Dental Pain Study of Analgesics in Patients Undergoing Molar Removal Phase 2